| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2000-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_888f1ca5043fcc1c199093ddb071048f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6086851758ebb18f76336f20f6ec5fa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad6bcfa12d4eb507bcdb7d4d1537fa4a |
| publicationDate |
2002-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-0013252-A |
| titleOfInvention |
Mycophenolate mofetil in combination with peg-ifn-alfa |
| abstract |
"MYCOPHENOLATE MOFETILE IN ASSOCIATION WITH PEG-IFN-ALFA". This invention relates to the use of a therapeutically effective amount of IFN- <244> or PEG-IFN- <244> in combination with a therapeutically effective amount of a pharmaceutically acceptable salt or mycophenolic acid prodrug for the production of drugs to treat patients with liver disease. The components are administered for a period of time at least long enough to reduce the amount of HCV RNA present in the patient's peripheral blood, to less than 100 copies / ml in 24 weeks after the end of treatment. |
| priorityDate |
1999-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |